+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023 - Product Image

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023

  • ID: 4771126
  • Report
  • Region: Global
  • 118 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
About this market

The high prevalence of lung cancer is one of the key factors expected to trigger the market growth during the forecast period. The increasing need for treatments coupled with the advances in therapeutics such as targeted therapy is encouraging more and more patients to undergo treatments using ALK inhibitor therapeutics. As a result, owing to the strong incidence rates of the disease and the increasing drug approvals, global ALK inhibitors market will register considerable growth during the forecast period. The analysts have predicted that the anaplastic lymphoma kinase (ALK) inhibitors market will register a CAGR of about 21% by 2023.

Market Overview

Presence of patient assistance programs

Patient assistance programs and reimbursement programs are expected to help with the high-cost regimen of ALK inhibitors to a large extent, which would encourage more patients to avail the treatment, thereby driving the market growth.

Adverse effects associated with therapeutics

Despite being highly efficacious, ALK inhibitors used for treatment NSCLC are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.

For the detailed list of factors that will drive and challenge the growth of the anaplastic lymphoma kinase (ALK) inhibitors market during 2019-2023, view the full report.

Competitive Landscape

The market appears to be concentrated with the presence of a few market players. ALK inhibitors have demonstrated efficacy in the oncology indications such as NSCLC, which has been encouraging vendors to extend their application to various other oncology indications through additional clinical trials. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Second-generation ALK inhibitors - Market size and forecast 2018-2023
  • First-generation ALK inhibitors - Market size and forecast 2018-2023
  • Third-generation ALK inhibitors - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Second-generation ALK inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Second-generation ALK inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 21: Second-generation ALK inhibitors pipeline
Exhibit 22: First-generation ALK inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Upcoming patent expiry of XALKORI
Exhibit 24: First-generation ALK inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 25: Third-generation ALK inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Lorlatinib pipeline
Exhibit 27: Third-generation ALK inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by type
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Patient assistance programs
Exhibit 47: Alternative therapies for oncology conditions
Exhibit 48: Side effects of ALK inhibitors
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Drugs with respect to their expanded indications
Exhibit 51: Vendor landscape
Exhibit 52: Landscape disruption
Exhibit 53: Vendors covered
Exhibit 54: Vendor classification
Exhibit 55: Market positioning of vendors
Exhibit 56: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 57: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 58: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 59: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 60: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 61: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 62: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 63: Novartis AG - Vendor overview
Exhibit 64: Novartis AG - Business segments
Exhibit 65: Novartis AG - Organizational developments
Exhibit 66: Novartis AG - Geographic focus
Exhibit 67: Novartis AG - Segment focus
Exhibit 68: Novartis AG - Key offerings
Exhibit 69: Novartis AG - Key customers
Exhibit 70: Pfizer Inc. - Vendor overview
Exhibit 71: Pfizer Inc. - Business segments
Exhibit 72: Pfizer Inc. - Organizational developments
Exhibit 73: Pfizer Inc. - Geographic focus
Exhibit 74: Pfizer Inc. - Segment focus
Exhibit 75: Pfizer Inc. - Key offerings
Exhibit 76: Pfizer Inc. - Key customers
Exhibit 77: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023

The analyst recognizes the following companies as the key players in the global anaplastic lymphoma kinase (ALK) inhibitors market: F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Commenting on the report, an analyst from the team said: “The latest trend gaining momentum in the market is the growing awareness about lung cancer.”

According to the report, one of the major drivers for this market is the high target affinity and specificity of ALK inhibitors.

Further, the report states that one of the major factors hindering the growth of this market is the preference for substitute products.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll